Categories: Gastrointestinal diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endometriosis

Summaries for Endometriosis

MedlinePlus: 41 What is endometriosis? The uterus, or womb, is the place where a baby grows when a person is pregnant. The uterus is lined with tissue (endometrium). Endometriosis is a disease in which tissue that is similar to the lining of the uterus grows in other places in your body. These patches of tissue are called "implants," "nodules," or "lesions." They are most often found: On or under the ovaries On the fallopian tubes, which carry egg cells from the ovaries to the uterus Behind the uterus On the tissues that hold the uterus in place On the bowels or bladder In rare cases, the tissue may grow on your lungs or in other parts of your body. What causes endometriosis? The cause of endometriosis is unknown. Who is at risk for endometriosis? Endometriosis can affect anyone who menstruates. Certain factors can raise or lower your risk of getting it. You are at higher risk if: You have a mother, sister, or daughter with endometriosis Your period started before age 11 Your monthly cycles are short (less than 27 days) Your menstrual cycles are heavy and last more than 7 days You have a lower risk if: You have been pregnant before Your periods started late in adolescence You breastfeed your babies What are the symptoms of endometriosis? The main symptoms of endometriosis are: Pelvic pain, which often happens during your period. Infertility Other possible symptoms include: Painful menstrual cramps, which may get worse over time Pain during or after sex Pain in the intestine or lower abdomen Pain with bowel movements or urination, usually during your period Heavy periods Spotting or bleeding between periods Digestive or gastrointestinal symptoms Fatigue or lack of energy How is endometriosis diagnosed? Surgery is the only way to know for sure that you have endometriosis. First, however, your health care provider will ask about your symptoms and medical history. You will have a pelvic exam and may have some imaging tests. The most common surgery to diagnose endometriosis is a laparoscopy. This is a type of surgery that uses a laparoscope, a thin tube with a camera and light. The surgeon inserts the laparoscope through a small cut in the skin. Your provider can make a diagnosis based on how the patches of endometriosis look. He or she may also do a biopsy to get a tissue sample. What are the treatments for endometriosis? There is no cure for endometriosis, but there are treatments for the symptoms. Your provider will work with you to decide which treatments would be best for you. Treatments for endometriosis pain include: Pain relievers, including nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen and a prescription medicine specifically for endometriosis. Providers may sometimes prescribe opioids for severe pain. Hormone therapy, including birth control pills, progestin therapy, and gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists cause a temporary menopause, but also help control the growth of endometriosis. Surgical treatments for severe pain, including procedures to remove the endometriosis patches or cut some nerves in the pelvis. The surgery may be a laparoscopy or major surgery. Treatments for infertility caused by endometriosis include: Laparoscopy to remove the endometriosis patches In vitro fertilization NIH: National Institute of Child Health and Human Development

MalaCards based summary: Endometriosis, also known as endometriosis, site unspecified, is related to endometriosis of ovary and endometrial adenocarcinoma, and has symptoms including pelvic pain and pain and other symptoms associated with female genital organs. An important gene associated with Endometriosis is ENDO1 (Endometriosis, Susceptibility To, 1), and among its related pathways/superpathways are miRNAs involvement in the immune response in sepsis and Cell differentiation - expanded index. The drugs Progesterone and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and skin.

PubMed Health : 63 Endometriosis: Endometriosis is one of the most common medical conditions affecting the abdomen (lower belly) in women. In endometriosis, the kind of tissue that normally lines the inside of the womb (endometrial tissue) also grows outside of it. The medical term for endometrial tissue that has grown outside of the womb is “endometrial implants.” Some women have them without knowing it. But other women experience endometriosis as a chronic disease that causes severe pain and fertility problems. It often takes years for endometriosis to be diagnosed as the cause of these problems. Until the diagnosis is made, many women try to cope with their pain somehow. They believe that the pain – even really bad pain – is a normal part of their menstrual period. There is currently no cure for endometriosis. But there are many things that can be done to relieve the symptoms. If treatment is adapted to suit women’s personal circumstances and the severity of their endometriosis, many can cope quite well with the disease. Like with other chronic conditions, it's important to get to know your own body and how it reacts, in order to find ways to manage the symptoms. Getting hold of good information and consulting experienced, supportive doctors can help.

Disease Ontology: 11 A female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body.

Wikipedia: 75 Endometriosis is a disease of the female reproductive system in which cells similar to those in the... more...

Related Diseases for Endometriosis

Diseases in the Endometriosis family:

Endometriosis 1

Diseases related to Endometriosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1007)
# Related Disease Score Top Affiliating Genes
1 endometriosis of ovary 32.6 MIR424 MIR145 MIR141
2 endometrial adenocarcinoma 30.6 MIR34C MIR200B MIR200A
3 rectal benign neoplasm 30.6 MIR99A MIR20A MIR145 MIR143
4 colonic benign neoplasm 30.2 MIR200A MIR145 MIR143
5 intestinal benign neoplasm 30.1 MIR20A MIR200A MIR143 MIR142
6 wilms tumor 1 30.0 WNT4 MIR142 MIR125A H19
7 periodontitis 29.9 MIR142 MIR125A CDKN2B-AS1
8 retinitis pigmentosa 11 29.8 MIR142 MIR126 MIR125A CDKN2B-AS1
9 ovarian cancer 29.6 MIR99A MIR424 MIR34C MIR29C MIR223 MIR200B
10 renal hypertension 29.6 MIR200B MIR200A MIR141
11 disease of mental health 29.6 MIR34C MIR223 MIR142 MIR126 MIR125A
12 rectum cancer 29.5 MIR99A MIR424 MIR20A MIR200A MIR145 MIR143
13 immune deficiency disease 29.5 MIR223 MIR20A MIR142 MIR126 MIR125A
14 gallbladder disease 29.5 MIR29C MIR145 MIR143 MIR142 MIR125A
15 cardiovascular system disease 29.4 MIR223 MIR145 MIR143 MIR142 MIR126 MIR125A
16 melanoma 29.4 MIR34C MIR200B MIR200A MIR141 MIR100 H19
17 multiple sclerosis 29.4 MIR223 MIR20A MIR145 MIR142 MIR125A
18 diabetes mellitus 29.3 MIR99A MIR223 MIR20A MIR145 MIR143 MIR126
19 bladder cancer 29.3 MIR99A MIR29C MIR223 MIR200A MIR145 MIR143
20 ovarian disease 29.3 MIR424 MIR223 MIR200B MIR200A MIR145 MIR143
21 peripheral nervous system disease 29.2 MIR200B MIR145 MIR143 MIR142 MIR141 MIR126
22 cerebrovascular disease 29.1 MIR223 MIR145 MIR143 MIR142 MIR126 MIR125A
23 lipoprotein quantitative trait locus 29.1 MIR223 MIR145 MIR143 MIR142 MIR126 MIR125A
24 uterine anomalies 29.1 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
25 cervical cancer 29.1 MIR424 MIR20A MIR200B MIR200A MIR196B MIR143
26 parkinson disease, late-onset 29.0 MIR34C MIR223 MIR142 MIR126 MIR125A H19
27 cervix carcinoma 29.0 MIR99A MIR34C MIR200A MIR142 MIR141
28 lung cancer susceptibility 3 29.0 MIR200B MIR200A MIR145 MIR143 MIR142 MIR141
29 human papillomavirus infectious disease 28.9 MIR223 MIR142 MIR125A MIR100
30 hypertension, essential 28.9 MIR424 MIR223 MIR145 MIR143 MIR141 MIR126
31 psoriasis 28.9 MIR20A MIR200A MIR142 MIR141 MIR100
32 kidney cancer 28.9 MIR424 MIR29C MIR20A MIR200B MIR145 MIR142
33 leukemia, acute lymphoblastic 28.8 MIR424 MIR223 MIR196B MIR142 MIR126 MIR125A
34 breast cancer 28.8 MIR29C MIR20A MIR200B MIR200A MIR145 MIR143
35 alzheimer disease, familial, 1 28.8 MIR223 MIR200B MIR143 MIR142 MIR126 MIR125A
36 skin disease 28.7 MIR29C MIR223 MIR20A MIR200B MIR142 MIR126
37 type 2 diabetes mellitus 28.7 MIR29C MIR223 MIR20A MIR145 MIR143 MIR142
38 arteries, anomalies of 28.7 MIR424 MIR29C MIR223 MIR20A MIR145 MIR143
39 leukemia, acute myeloid 28.6 MIR424 MIR34C MIR223 MIR145 MIR142 MIR126
40 breast disease 28.4 MIR34C MIR29C MIR223 MIR20A MIR200B MIR200A
41 leukemia, chronic lymphocytic 28.3 MIR424 MIR29C MIR223 MIR20A MIR200B MIR145
42 lymphoma, non-hodgkin, familial 28.3 MIR424 MIR34C MIR223 MIR20A MIR200B MIR200A
43 prostate cancer 28.2 MIR99A MIR223 MIR20A MIR200B MIR145 MIR143
44 lymphatic system disease 28.2 MIR424 MIR34C MIR29C MIR223 MIR20A MIR200B
45 hematologic cancer 28.1 MIR424 MIR34C MIR29C MIR223 MIR20A MIR200B
46 body mass index quantitative trait locus 11 28.0 MIR99A MIR424 MIR223 MIR20A MIR143 MIR142
47 bladder disease 27.9 MIR99A MIR424 MIR29C MIR223 MIR200A MIR145
48 urinary system disease 27.9 MIR424 MIR29C MIR223 MIR20A MIR200B MIR200A
49 gastric cancer 27.9 MIR223 MIR20A MIR196B MIR145 MIR143 MIR142
50 gastrointestinal system disease 27.8 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A

Comorbidity relations with Endometriosis via Phenotypic Disease Network (PDN):


Graphical network of the top 20 diseases related to Endometriosis:

Diseases related to Endometriosis

Symptoms & Phenotypes for Endometriosis

UMLS symptoms related to Endometriosis:

pelvic pain; pain and other symptoms associated with female genital organs

Drugs & Therapeutics for Endometriosis

PubMed Health treatment related to Endometriosis: 63

There is currently no “cure” for endometriosis – in other words, there are no treatments that can fight what is causing it. But various treatments can help relieve the symptoms, temporarily or permanently. The medication options include painkillers, hormonal contraception and stronger hormone therapy . Painkillers only relieve the symptoms, whereas hormone-based treatments slow down the growth of endometrial implants . Surgery is also an option. The aim of surgery for endometriosis is usually to remove as many endometrial implants as possible. Sometimes surgery is even necessary – for instance, if endometriosis is affecting bowel or bladder function.

Drugs for Endometriosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
Follitropin Approved, Vet_approved Phase 4 97048-13-0, 146479-72-3, 9002-68-0 62819
Danazol Approved Phase 4 17230-88-5 28417
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Quinagolide Approved, Investigational Phase 4 87056-78-8
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
Sage Approved Phase 4
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
Simvastatin Approved Phase 4 79902-63-9 54454
Atorvastatin Approved Phase 4 134523-00-5 60823
Drospirenone Approved Phase 4 67392-87-4 68873
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
Tibolone Approved, Investigational Phase 4 5630-53-5 5470 444008
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109
Norgestrel Approved Phase 4 6533-00-2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
Gallopamil Investigational Phase 4 16662-47-8 1234
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
Gestodene Investigational Phase 4 60282-87-3 3033968
Resveratrol Investigational Phase 4 501-36-0 445154
Triptorelin Pamoate Phase 4
Ulipristal acetate Phase 4 126784-99-4 13559282 130904
39 Adjuvants, Immunologic Phase 4
40 Immunologic Factors Phase 4
41 Chorionic Gonadotropin Phase 4
42 Viscosupplements Phase 4
43 Neuromuscular Nondepolarizing Agents Phase 4
44 Neuromuscular Blocking Agents Phase 4
45 Dopamine agonists Phase 4
Vitamin D2 Phase 4 3249
47 Ergocalciferols Phase 4
48 Omega 3 Fatty Acid Phase 4
49 Somatomedin B Phase 4
50 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 590)
# Name Status NCT ID Phase Drugs
1 Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest Unknown status NCT02575248 Phase 4 Dienogest 2mg;Clomiphene citrate 5 mg
2 Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving, Using Indocyanine Green Injection. Feasibility Study Unknown status NCT03080558 Phase 4 Indocyanine green
3 A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis Unknown status NCT00654524 Phase 4 gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
4 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
5 A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain Unknown status NCT02031523 Phase 4 Sanjie analgesic capsule;placebo
6 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
7 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
8 Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier Unknown status NCT02165917 Phase 4
9 A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery Unknown status NCT02385448 Phase 4 Dienogest;Microgynon
10 Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size Unknown status NCT03789123 Phase 4 Estradiol valerate/dienogest
11 Trans-vaginal Aspiration With or Without Injection of Surgicel for Treatment of Small Ovarian Endometrioma Before ICSI Cycles. A Randomized Controlled Trial Unknown status NCT03784404 Phase 4 Intracytoplasmic sperm injection
12 IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates. Completed NCT01682642 Phase 4 Zoladex
13 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
14 SAGE: Supplementation in Adolescent Girls With Endometriosis Completed NCT02387931 Phase 4
15 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
16 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
17 Do Endometrial Implantation Markers Predict in Vitro Fertilization-embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension? Completed NCT00621179 Phase 4 Leuprolide acetate in depot suspension
18 Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis Completed NCT00286351 Phase 4 Combined treatment with Arimidex and Zoladex before IVF
19 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
20 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
21 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
22 A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment Completed NCT01581359 Phase 4 Triptorelin acetate
23 Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial Completed NCT02158845 Phase 4 LNG-IUS: levonorgestrel intrauterine system;GnRHa: leuprolide
24 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
25 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
26 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
27 Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. Completed NCT00625950 Phase 4
28 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Completed NCT02214550 Phase 4 microgestin 1/20
29 The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial Recruiting NCT04554693 Phase 4 Metronidazole Oral;Placebo
30 Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis Recruiting NCT05059626 Phase 4 simvastatin 10mg;Bazedoxifene 20/Estrogens,Con 0.45Mg Tb;Placebo
31 Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis: a Prospective, Double-blind, Randomized Controlled Trial Recruiting NCT05560230 Phase 4 Clonidine;Isotonic saline
32 Low Dose of Aspirin for the Management of Endometriosis-associated Pelvic Pain: a Randomized, Open, Controlled Trial Recruiting NCT05156879 Phase 4 Aspirin;Drospirenone ethinyl estradiol
33 MicroRNA Activation of LOX-1 Mechanisms in Endometriosis Recruiting NCT05331053 Phase 4 Atorvastatin
34 Goserline Acetate Versus Dienogest in Treatment of Pain Associated With Endometriosis Recruiting NCT05013242 Phase 4 Zoladex;Visanne
35 The Efficacy and Safety of Xuefu Zhuyu Capsule in Treating "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome): a Randomized, Double-blind, Placebo-controlled, Adaptive Enrichment, Multicenter Controlled Trial Recruiting NCT04218487 Phase 4 Xuefu-Zhuyu Capsule;placebo
36 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
37 Beijing University of Chinese Medicine Not yet recruiting NCT04942015 Phase 4 Honghuaruyi Wan;Placebo of Honghuaruyi Wan
38 A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
39 Peritoneal Cavity Conditioning During Laparoscopic Surgery Decreases Postoperative Pain, Inflammatory Reaction and Postoperative Adhesions Terminated NCT01344486 Phase 4
40 Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery Unknown status NCT01973816 Phase 3 Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;;Cyproterone acetate 50 mg; estradiol 0.5% percutaneous;Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
41 Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) Unknown status NCT00458458 Phase 3 Norethindrone Acetate (NA);GnRH Agonist (Lupron Depot)
42 The Role of the Subcutaneous Progesterone in Luteal Phase Supplementation in Patients With Endometriosis Unknown status NCT02793908 Phase 3 Pleyris;Crinone8
43 Study Comparing Laparoscopy Versus Laparotomy in the Treatment of Colorectal Endometriosis Unknown status NCT00939861 Phase 3
44 Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial Unknown status NCT01125488 Phase 3 GnRH agonist (triptorelin)
45 Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis: A Randomized Controlled Trial Unknown status NCT02470169 Phase 3 Merional;Choriomon
46 The in Vitro Fertilisation - Lipiodol Uterine Bathing Effect Study Unknown status NCT00894946 Phase 3
47 Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis Completed NCT01942122 Phase 2, Phase 3 DLBS1442 100;Mefenamic acid;DLBS1442 200
48 A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis Completed NCT00455845 Phase 3
49 Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis Completed NCT02271958 Phase 2, Phase 3 Mifepristone;PLACEBO
50 Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain Completed NCT02143713 Phase 3 Elagolix

Search NIH Clinical Center for Endometriosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Ethynodiol Diacetate
Goserelin Acetate
hydroxyprogesterone caproate (USP)
Leuprolide Acetate
Nafarelin Acetate
norethindrone acetate

Cochrane evidence based reviews: endometriosis

Genetic Tests for Endometriosis

Genetic tests related to Endometriosis:

# Genetic test Affiliating Genes
1 Endometriosis 28

Anatomical Context for Endometriosis

Organs/tissues related to Endometriosis:

MalaCards : Uterus, Ovary, Skin, Appendix, Endothelial, Smooth Muscle, Bone Marrow

Publications for Endometriosis

Articles related to Endometriosis:

(show top 50) (show all 26637)
# Title Authors PMID Year
A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations. 62 41
36266431 2022
The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial. 62 41
36195878 2022
Pain Reduction With an Immersive Digital Therapeutic Tool in Women Living With Endometriosis-Related Pelvic Pain: Randomized Controlled Trial. 62 41
36129733 2022
MicroRNA-regulated pathways associated with endometriosis. 62 46
19074548 2009
Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. 53 62
19338989 2010
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 53 62
19342032 2010
Letrozole and norethisterone acetate in colorectal endometriosis. 53 62
20227163 2010
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. 53 62
19324337 2010
Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane. 53 62
19345347 2010
Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFkappaB-dependent pathway. 53 62
19903119 2010
[Aromatase and endometriosis: myth or reality]. 53 62
20430669 2010
[Treatment of endometriosis by aromatase inhibitors: efficacy and side effects]. 53 62
20430665 2010
The roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis. 53 62
20172870 2010
Steroidogenic factor-1 expression in ovarian endometriosis. 53 62
19875956 2010
Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium. 53 62
20155281 2010
Proteomic analysis of endometrium from fertile and infertile patients suggests a role for apolipoprotein A-I in embryo implantation failure and endometriosis. 53 62
20008415 2010
Estrogen and progesterone receptors in smooth muscle component of deep infiltrating endometriosis. 53 62
19217090 2010
Effect of human seminal fluid on the growth of endometrial cells of women with endometriosis. 53 62
20092935 2010
Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. 53 62
20492386 2010
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. 53 62
19932734 2010
[Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in human and nude mouse ectopic endometrium and the effect of estrogen and progestin on their expression]. 53 62
20423842 2010
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. 53 62
20074813 2010
Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. 53 62
20007161 2010
Regulation of monocyte chemotactic protein-1 expression in human endometrial endothelial cells by sex steroids: a potential mechanism for leukocyte recruitment in endometriosis. 53 62
19933497 2010
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. 53 62
20023295 2010
Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. 53 62
20137818 2010
Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. 53 62
20007614 2010
Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. 53 62
19945964 2010
Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. 53 62
20068324 2010
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. 53 62
20085636 2010
Association of interleukin 1beta gene (+3953) polymorphism and severity of endometriosis in Turkish women. 53 62
19757173 2010
Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis. 53 62
19892605 2010
Haptoglobin expression in endometrioid adenocarcinoma of the uterus. 53 62
19801537 2010
Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression. 53 62
19647233 2010
Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. 53 62
20104427 2010
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. 53 62
20108182 2010
Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. 53 62
20104430 2010
Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. 53 62
19898423 2010
Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions. 53 62
19917472 2009
HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility. 53 62
19736237 2009
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis. 53 62
20112494 2009
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. 53 62
19726448 2009
Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. 53 62
18976754 2009
Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain. 53 62
19958132 2009
Fenofibrate causes regression of endometriotic implants: a rat model. 53 62
19580963 2009
Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. 53 62
20512287 2009
Recent patent trends in the field of progesterone receptor agonists and modulators. 53 62
19785507 2009
Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. 53 62
19661147 2009
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. 53 62
19903048 2009
Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. 53 62
19661125 2009

Variations for Endometriosis

ClinVar genetic disease variations for Endometriosis:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL1B NM_000576.3(IL1B):c.315C>T (p.Phe105=) SNV Affects
869137 rs1143634 GRCh37: 2:113590390-113590390
GRCh38: 2:112832813-112832813
2 TNF NM_000594.3(TNF):c.-488G>A SNV Affects
225964 rs1800629 GRCh37: 6:31543031-31543031
GRCh38: 6:31575254-31575254
3 FAM163A t(1;5)(q25;q12) TRANS Uncertain Significance
810664 GRCh37: 1:179785309-179785316
4 overlap with 8 genes NC_000002.12:g.(?_112924872)_(113105404_?)del DEL Uncertain Significance
1339474 GRCh37:
GRCh38: 2:112924872-113105404

Expression for Endometriosis

LifeMap Discovery
Genes differentially expressed in tissues of Endometriosis patients vs. healthy controls: 35 (show top 50) (show all 83)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PTGIS prostaglandin I2 synthase Uterus + 5.41 0.000
2 MYH11 myosin heavy chain 11 Uterus + 4.87 0.001
3 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Uterus + 4.81 0.000
4 CNN1 calponin 1 Uterus + 4.71 0.000
5 TAGLN transgelin Uterus + 4.63 0.000
6 PAEP progestagen associated endometrial protein Uterus + 4.63 0.013
7 PRELP proline and arginine rich end leucine rich repeat protein Uterus + 4.59 0.000
8 C7 complement C7 Uterus + 4.54 0.003
9 ACTG2 actin gamma 2, smooth muscle Uterus + 4.48 0.003
10 TCF21 transcription factor 21 Uterus + 4.45 0.000
11 HPGD 15-hydroxyprostaglandin dehydrogenase Uterus - 4.42 0.001
12 CCN5 cellular communication network factor 5 Uterus + 4.11 0.001
13 AQP1 aquaporin 1 (Colton blood group) Uterus + 4.10 0.000
14 EHF ETS homologous factor Uterus - 4.10 0.000
15 FOS Fos proto-oncogene, AP-1 transcription factor subunit Uterus + 4.09 0.000
16 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Uterus + 4.07 0.000
17 SLC3A1 solute carrier family 3 member 1 Uterus - 4.05 0.010
18 LMNB1 lamin B1 Uterus - 4.05 0.000
19 SLC26A4 solute carrier family 26 member 4 Uterus - 3.99 0.000
20 DPT dermatopontin Uterus + 3.98 0.000
21 DES desmin Uterus + 3.97 0.001
22 KCNMB1 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Uterus + 3.96 0.001
23 GATA6 GATA binding protein 6 Uterus + 3.89 0.004
24 FZD7 frizzled class receptor 7 Uterus + 3.89 0.000
25 LEFTY2 left-right determination factor 2 Uterus + 3.88 0.001
26 SLC26A4 solute carrier family 26 member 4 Uterus - 3.87 0.001
27 HPGD 15-hydroxyprostaglandin dehydrogenase Uterus - 3.86 0.001
28 ACKR1 atypical chemokine receptor 1 (Duffy blood group) Uterus + 3.84 0.001
29 EFHC2 EF-hand domain containing 2 Uterus - 3.75 0.000
30 PDLIM3 PDZ and LIM domain 3 Uterus + 3.72 0.001
31 GPC3 glypican 3 Uterus + 3.71 0.003
32 IL20RA interleukin 20 receptor subunit alpha Uterus - 3.70 0.000
33 MYL9 myosin light chain 9 Uterus + 3.70 0.001
34 VNN1 vanin 1 Uterus - 3.69 0.008
35 CTSZ cathepsin Z Uterus - 3.68 0.000
36 EHF ETS homologous factor Uterus - 3.67 0.000
37 LMNB1 lamin B1 Uterus - 3.61 0.000
38 CLU clusterin Uterus + 3.58 0.002
39 ACTA2 actin alpha 2, smooth muscle Uterus + 3.57 0.000
40 TCEAL2 transcription elongation factor A like 2 Uterus + 3.53 0.001
41 LMOD1 leiomodin 1 Uterus + 3.52 0.003
42 LMO3 LIM domain only 3 Uterus + 3.51 0.002
43 TPD52 tumor protein D52 Uterus - 3.50 0.000
44 SYNPO synaptopodin Uterus + 3.48 0.001
45 KLF2 KLF transcription factor 2 Uterus + 3.44 0.000
46 AOC3 amine oxidase copper containing 3 Uterus + 3.44 0.003
47 KCNK3 potassium two pore domain channel subfamily K member 3 Uterus + 3.44 0.007
48 ZBBX zinc finger B-box domain containing Uterus - 3.43 0.001
49 FMO1 flavin containing dimethylaniline monoxygenase 1 Uterus + 3.43 0.000
50 ZBBX zinc finger B-box domain containing Uterus - 3.42 0.002
Search GEO for disease gene expression data for Endometriosis.

Pathways for Endometriosis

GO Terms for Endometriosis

Cellular components related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 WNT4 MIR99A MIR424 MIR29C MIR223 MIR20A
2 RISC complex GO:0016442 9.81 H19 MIR100 MIR125A MIR126 MIR141 MIR142
3 extracellular vesicle GO:1903561 9.43 MIR99A MIR29C MIR20A MIR126 MIR125A MIR100

Biological processes related to Endometriosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.99 WNT4 MIR29C MIR145 MIR126
2 negative regulation of gene expression GO:0010629 9.92 WNT4 MIR29C MIR20A MIR200B MIR125A MIR100
3 miRNA-mediated gene silencing GO:0035195 9.8 H19 MIR100 MIR125A MIR126 MIR141 MIR142
4 negative regulation of inflammatory response GO:0050728 9.73 MIR126 MIR141 MIR142 MIR145 MIR20A MIR223
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 MIR200A MIR143 MIR126
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.69 MIR424 MIR29C MIR20A
7 negative regulation of protein kinase B signaling GO:0051898 9.67 MIR34C MIR29C MIR20A MIR145
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.63 MIR424 MIR29C MIR126
9 negative regulation of angiogenesis GO:0016525 9.63 MIR424 MIR29C MIR200B MIR145 MIR143 MIR125A
10 angiotensin-activated signaling pathway GO:0038166 9.58 MIR145 MIR143
11 negative regulation of receptor signaling pathway via STAT GO:1904893 9.58 MIR99A MIR125A
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR34C MIR20A
13 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.56 MIR99A MIR125A
14 aorta smooth muscle tissue morphogenesis GO:0060414 9.54 MIR145 MIR143
15 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.52 MIR141 MIR125A
16 regulation of phenotypic switching GO:1900239 9.49 MIR143 MIR145
17 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.48 MIR20A MIR143
18 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
19 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR29C MIR20A MIR200B MIR145 MIR126 MIR100
20 negative regulation of interleukin-16 production GO:0032699 9.4 MIR145 MIR125A

Molecular functions related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.77 MIR424 MIR34C MIR29C MIR223 MIR20A MIR200B
2 mRNA base-pairing translational repressor activity GO:1903231 9.5 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A

Sources for Endometriosis

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....